Germinal center B cell and t follicular helper cell responses to viral vector and protein-in-adjuvant vaccines

Journal of Immunology

Volumn 197, Issue 4, 2016, Pages 1242-1251

  Wang, Chuan ^a   Hart, Matthew ^a   Chui, Cecilia ^a   Ajuogu, Augustine ^a   Brian, Iona J ^a   De Cassan, Simone C ^a   Borrow, Persephone ^a   Draper, Simon J ^a   Douglas, Alexander D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM POTASSIUM SULFATE; IMMUNOGLOBULIN G; OVALBUMIN; POXVIRUS VECTOR; PROTEIN IN ADJUVANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR; ANTIGEN; IMMUNOLOGICAL ADJUVANT;

ADENOVIRIDAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GERMINAL CENTER; HELPER CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOHISTOLOGY; INNATE IMMUNITY; MOUSE; NONHUMAN; POXVIRIDAE; PRIORITY JOURNAL; T FOLLICULAR HELPER CELL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENE VECTOR; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; B-LYMPHOCYTES; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; GERMINAL CENTER; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; OVALBUMIN; T-LYMPHOCYTES, HELPER-INDUCER; VIRAL VACCINES;

EID: 84983784130     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502472     Document Type: Article

References (51)

1. Guy, B. 2007. The perfect mix: Recent progress in adjuvant research. Nat. Rev. Microbiol. 5: 505-517.
2. O'Hagan, D. T., and E. De Gregorio. 2009. The path to a successful vaccine adjuvant-'the long and winding road.' Drug Discov. Today 14: 541-551.
3. Draper, S. J., and J. L. Heeney. 2009. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8: 62-73.
4. Draper, S. J., A. C. Moore, A. L. Goodman, C. A. Long, A. A. Holder, S. C. Gilbert, F. Hill, and A. V. Hill. 2008. Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 14: 819-821.
5. de Cassan, S. C., and S. J. Draper. 2013. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev. Vaccines 12: 365-378.
6. Draper, S. J., M. G. Cottingham, and S. C. Gilbert. 2013. Utilizing poxviral vectored vaccines for antibody induction-progress and prospects. Vaccine 31: 4223-4230.
7. Douglas, A. D., S. C. de Cassan, M. D. Dicks, S. C. Gilbert, A. V. Hill, and S. J. Draper. 2010. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28: 7167-7178.
8. de Cassan, S. C., E. K. Forbes, A. D. Douglas, A. Milicic, B. Singh, P. Gupta, V. S. Chauhan, C. E. Chitnis, S. C. Gilbert, A. V. Hill, and S. J. Draper. 2011. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J. Immunol. 187: 2602-2616.
9. Draper, S. J., S. Biswas, A. J. Spencer, E. J. Remarque, S. Capone, M. Naddeo, M. D. J. Dicks, B. W. Faber, S. C. de Cassan, A. Folgori, et al. 2010. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol. 185: 7583-7595.
10. Sheehy, S. H., C. J. Duncan, S. C. Elias, K. A. Collins, K. J. Ewer, A. J. Spencer, A. R. Williams, F. D. Halstead, S. E. Moretz, K. Miura, et al. 2011. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. 19: 2269-2276.
11. Hodgson, S. H., P. Choudhary, S. C. Elias, K. H. Milne, T. W. Rampling, S. Biswas, I. D. Poulton, K. Miura, A. D. Douglas, D. G. Alanine, et al. 2014. Combining viral vectored and protein-in-adjuvant vaccines against the bloodstage malaria antigen AMA1: Report on a phase 1a clinical trial. Mol. Ther. 22: 2142-2154.
12. Geiben-Lynn, R., J. R. Greenland, K. Frimpong-Boateng, and N. L. Letvin. 2008. Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses. Clin. Vaccine Immunol. 15: 691-696.
13. Cockburn, I. A., S. Chakravarty, M. G. Overstreet, A. García-Sastre, and F. Zavala. 2008. Memory CD8+ T cell responses expand when antigen presentation overcomes T cell self-regulation. J. Immunol. 180: 64-71.
14. Zhu, J., X. Huang, and Y. Yang. 2007. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 81: 3170-3180.
15. Zhu, J., X. Huang, and Y. Yang. 2007. Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus. J. Immunol. 178: 3505-3510.
16. Appledorn, D. M., S. Patial, A. McBride, S. Godbehere, N. Van Rooijen, N. Parameswaran, and A. Amalfitano. 2008. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 181: 2134-2144.
17. Rhee, E. G., J. N. Blattman, S. P. Kasturi, R. P. Kelley, D. R. Kaufman, D. M. Lynch, A. La Porte, N. L. Simmons, S. L. Clark, B. Pulendran, et al. 2011. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J. Virol. 85: 315-323.
18. Shlomchik, M. J., and F. Weisel. 2012. Germinal center selection and the development of memory B and plasma cells. Immunol. Rev. 247: 52-63.
19. Nutt, S. L., and D. M. Tarlinton. 2011. Germinal center B and follicular helper T cells: siblings, cousins or just good friends? Nat. Immunol. 12: 472-477.
20. Vargas-Inchaustegui, D. A., A. Demers, J. M. Shaw, G. Kang, D. Ball, I. Tuero, T. Musich, V. Mohanram, T. Demberg, T. S. Karpova, et al. 2016. Vaccine induction of lymph node-resident simian immunodeficiency virus Env-specific T follicular helper cells in Rhesus macaques. J. Immunol. 196: 1700-1710.
21. Colloca, S., E. Barnes, A. Folgori, V. Ammendola, S. Capone, A. Cirillo, L. Siani, M. Naddeo, F. Grazioli, M. L. Esposito, et al. 2012. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4: 115ra2.
22. Quinn, K. M., A. Da Costa, A. Yamamoto, D. Berry, R. W. Lindsay, P. A. Darrah, L. Wang, C. Cheng, W. P. Kong, J. G. Gall, et al. 2013. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J. Immunol. 190: 2720-2735.
23. Quinn, K. M., D. E. Zak, A. Costa, A. Yamamoto, K. Kastenmuller, B. J. Hill, G. M. Lynn, P. A. Darrah, R. W. Lindsay, L. Wang, et al. 2015. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J. Clin. Invest. 125: 1129-1146.
24. Ophorst, O. J., K. Radosević, J. M. Klap, J. Sijtsma, G. Gillissen, R. Mintardjo, M. J. van Ooij, L. Holterman, A. Companjen, J. Goudsmit, and M. J. Havenga. 2007. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 25: 6501- 6510.
25. Ledgerwood, J. E., A. D. DeZure, D. A. Stanley, L. Novik, M. E. Enama, N. M. Berkowitz, Z. Hu, G. Joshi, A. Ploquin, S. Sitar, et al. 2014. Chimpanzee adenovirus vector Ebola vaccine - preliminary report. N. Engl. J. Med. DOI:10.1056/NEJMoa1410863.
26. Green, C. A., E. Scarselli, C. J. Sande, A. J. Thompson, C. M. de Lara, K. S. Taylor, K. Haworth, M. Del Sorbo, B. Angus, L. Siani, et al. 2015. Chimpanzee adenovirus- And MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci. Transl. Med. 7: 300ra126.
27. Pastoret, P. P., and B. Brochier. 1996. The development and use of a vacciniarabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. Epidemiol. Infect. 116: 235-240.
28. Webster, D. P., S. Dunachie, J. M. Vuola, T. Berthoud, S. Keating, S. M. Laidlaw, S. J. McConkey, I. Poulton, L. Andrews, R. F. Andersen, et al. 2005. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. USA 102: 4836-4841.
29. Frey, S. E., P. L. Winokur, H. Hill, J. B. Goll, P. Chaplin, and R. B. Belshe. 2014. Phase II randomized, double-blinded comparison of a single high dose (5310(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1310(8) TCID50) in healthy vaccinia-naïve individuals. Vaccine 32: 2732-2739.
30. Volz, A., A. Kupke, F. Song, S. Jany, R. Fux, H. Shams-Eldin, J. Schmidt, C. Becker, M. Eickmann, S. Becker, and G. Sutter. 2015. Protective efficacy of recombinant modified vaccinia virus Ankara delivering middle east respiratory syndrome Coronavirus spike glycoprotein. J. Virol. 89: 8651-8656.
31. Ramírez, J. C., M. M. Gherardi, and M. Esteban. 2000. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- And T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74: 923-933.
32. de Cassan, S. C., A. R. Shakri, D. Llewellyn, S. C. Elias, J. S. Cho, A. L. Goodman, J. Jin, A. D. Douglas, R. Suwanarusk, F. H. Nosten, et al. 2015. Preclinical assessment of viral vectored and protein vaccines targeting the Duffybinding protein region II of Plasmodium vivax. Front. Immunol. 6: 348.
33. Moon, J. J., H. Suh, A. Bershteyn, M. T. Stephan, H. Liu, B. Huang, M. Sohail, S. Luo, S. H. Um, H. Khant, et al. 2011. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10: 243-251.
34. Podda, A., and G. Del Giudice. 2003. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2: 197-203.
35. Garçon, N., D. W. Vaughn, and A. M. Didierlaurent. 2012. Development and evaluation of AS03, an Adjuvant System containing a-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11: 349-366.
36. Biswas, S., M. D. Dicks, C. A. Long, E. J. Remarque, L. Siani, S. Colloca, M. G. Cottingham, A. A. Holder, S. C. Gilbert, A. V. Hill, and S. J. Draper. 2011. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One 6: E20977.
37. Forbes, E. K., S. Biswas, K. A. Collins, S. C. Gilbert, A. V. Hill, and S. J. Draper. 2011. Combining liver- And blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference. J. Immunol. 187: 3738-3750.
38. Suzuki, T., K. Kitajima, Y. Emori, Y. Inoue, and S. Inoue. 1997. Site-specific de- N-glycosylation of diglycosylated ovalbumin in hen oviduct by endogenous peptide: N-glycanase as a quality control system for newly synthesized proteins. Proc. Natl. Acad. Sci. USA 94: 6244-6249.
39. Sridhar, S., A. Reyes-Sandoval, S. J. Draper, A. C. Moore, S. C. Gilbert, G. P. Gao, J. M. Wilson, and A. V. Hill. 2008. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J. Virol. 82: 3822-3833.
40. Smith, G. L., M. Mackett, and B. Moss. 1983. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302: 490- 495.
41. Earl, P. L., B. Moss, L. S. Wyatt, and M. W. Carroll. 2001. Generation of recombinant vaccinia viruses. Curr. Protoc. Mol. Biol. Chapter 16: Unit16 17.
42. Douglas, A. D., G. C. Baldeviano, C. M. Lucas, L. A. Lugo-Roman, C. Crosnier, S. J. Bartholdson, A. Diouf, K. Miura, L. E. Lambert, J. A. Ventocilla, et al. 2015. A PfRH5-based vaccine is efficacious against heterologous strain bloodstage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe 17: 130-139.
43. Miura, K., A. C. Orcutt, O. V. Muratova, L. H. Miller, A. Saul, and C. A. Long. 2008. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vasccine 26: 193-200.
44. Wang, Y., and D. Bhattacharya. 2014. Adjuvant-specific regulation of long-term antibody responses by ZBTB20. J. Exp. Med. 211: 841-856.
45. Takahashi, Y., P. R. Dutta, D. M. Cerasoli, and G. Kelsoe. 1998. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. J. Exp. Med. 187: 885- 895.
46. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer- Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96.
47. Crotty, S. 2014. T follicular helper cell differentiation, function, and roles in disease. Immunity 41: 529-542.
48. Guzman, E., C. Cubillos-Zapata, M. G. Cottingham, S. C. Gilbert, H. Prentice, B. Charleston, and J. C. Hope. 2012. Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation. J. Virol. 86: 5452-5466.
49. Wu, T. Y., M. Singh, A. T. Miller, E. De Gregorio, F. Doro, U. D'Oro, D. A. Skibinski, M. L. Mbow, S. Bufali, A. E. Herman, et al. 2014. Rational design of small molecules as vaccine adjuvants. Sci. Transl. Med. 6: 263ra160.
50. Sheehy, S. H., C. J. Duncan, S. C. Elias, P. Choudhary, S. Biswas, F. D. Halstead, K. A. Collins, N. J. Edwards, A. D. Douglas, N. A. Anagnostou, et al. 2012. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20: 2355-2368.
51. Rampling, T., K. Ewer, G. Bowyer, D. Wright, E. B. Imoukhuede, R. Payne, F. Hartnell, M. Gibani, C. Bliss, A. Minhinnick, et al. 2016. A monovalent chimpanzee adenovirus ebola vaccine-preliminary report. N. Engl. J. Med. 374: 1635-1646.